References
- Collier CN, Harper JC, Cantrell WC, Wang W, Foster KW, Elewski BE. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008; 58: 56–9
- Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999; 41: 577–80
- Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J. 1979; 1: 1109–10
- Goodman GJ. Post acne scarring: A review. J Cosmet Laser Ther. 2003; 5: 77–95
- Goodman GJ, Baron JA. The management of postacne scarring. Dermatol Surg. 2007; 33: 1175–88
- Simamora P, Chern W. Poly-L-lactic acid: An overview. J Drugs Dermatol. 2006; 5: 436–40
- Vleggaar D. Facial volumetric correction with injectable poly-L-lactic acid. Dermatol Surg. 2005; 31: 1511–17
- Sculptra [prescribing information]. Berwyn, PA: Dermik Laboratories; 2007.
- Mest DR, Humble G. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: The US experience. Dermatol Surg. 2006; 32: 1336–45
- Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol. 2005; 52: 233–9
- Moyle GJ, Lysakova L, Brown S, Sibtain N, Healy J, Priest C, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med. 2004; 5: 82–7
- Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med. 2006; 7: 181–5
- Valantin M-A, Aubron-olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, et al. Polylactic acid implants (New-Fill®) to correct facial lipoatrophy in HIV-infected patients: Results of the open-label study VEGA. AIDS. 2003; 17: 2471–7
- Rendon MI, Cosmetic Study Trial Group. Efficacy and safety of injectable poly-L-lactic acid (PLLA) and human-derived collagen in the correction of nasolabial fold wrinkles (NLFWS). 2008.
- Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988; 124: 869–71
- Kouzi SA, Nuzum DS. Arnica for bruising and swelling. Am J Health Syst Pharm. 2007; 64: 2434–43
- Mackay D, Miller AL. Nutritional support for wound healing. Altern Med Rev. 2003; 8: 359–77
- Seeley BM, Denton AB, Ahn MS, Maas CS. Effect of homeopathic Arnica montana on bruising in face-lifts: Results of a randomized, double-blind, placebo-controlled clinical trial. Arch Facial Plast Surg. 2006; 8: 54–9
- Beer K. A single-center, open-label study on the use of injectable poly-L-lactic acid for the treatment of moderate to severe scarring from acne or varicella. Dermatol Surg. 2007; 33: S159–S167
- Gogolewski S, Jovanovic M, Perren SM, Dillon JG, Hughes MK. Tissue response and in vivo degradation of selected polyhydroxyacids: Polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J Biomed Mater Res. 1993; 27: 1135–48
- Tunc DC, Jadhav B. Development of absorbable, ultra high strength poly(lactides). Progress in biomedical polymers., CG Gebelein, RL Dunn. Plenum Press, New York, NY 1990; 239–48
- Vleggaar D, Bauer U. Facial enhancement and the European experience with Sculptra™ (poly-l-lactic acid). J Drugs Dermatol. 2004; 3: 542–7
- Werschler WP, Smith SA. Mechanism of action of poly-l-lactic acid: A stimulatory dermal filler. J Drugs Dermatol. 2007; 6
- Goldberg DJ, Amin S, Hussain M. Acne scar correction using calcium hydroxylapatite in a carrier-based gel. J Cosmet Laser Ther. 2006; 8: 134–6